Forsta AP Fonden Acquires 6,800 Shares of Eli Lilly and Company $LLY

Forsta AP Fonden lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 3.1% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 223,051 shares of the company’s stock after buying an additional 6,800 shares during the quarter. Eli Lilly and Company comprises 1.1% of Forsta AP Fonden’s portfolio, making the stock its 12th biggest holding. Forsta AP Fonden’s holdings in Eli Lilly and Company were worth $173,875,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in LLY. PNC Financial Services Group Inc. grew its stake in shares of Eli Lilly and Company by 97.5% during the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after purchasing an additional 50,002,551 shares during the last quarter. Nuveen LLC acquired a new position in Eli Lilly and Company during the 1st quarter worth $4,613,912,000. Vanguard Group Inc. boosted its position in Eli Lilly and Company by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock valued at $65,432,218,000 after buying an additional 4,975,395 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in shares of Eli Lilly and Company by 106.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock valued at $1,154,508,000 after buying an additional 765,010 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in shares of Eli Lilly and Company by 13.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock valued at $4,808,443,000 after buying an additional 682,203 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 2.2%

NYSE:LLY opened at $987.48 on Wednesday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $999.95. The stock has a 50-day moving average price of $809.69 and a two-hundred day moving average price of $776.47. The stock has a market cap of $933.55 billion, a price-to-earnings ratio of 64.54, a PEG ratio of 1.21 and a beta of 0.43. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same quarter last year, the firm posted $1.18 earnings per share. Eli Lilly and Company’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 29.35%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on LLY shares. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Daiwa Capital Markets downgraded shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price on the stock. in a research report on Sunday, August 17th. BMO Capital Markets lifted their price target on shares of Eli Lilly and Company from $930.00 to $1,100.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Finally, UBS Group raised their price objective on shares of Eli Lilly and Company from $895.00 to $1,080.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $981.89.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.